Asep Medical Holdings Inc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Richard Heinzl
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1055 West Hastings Street Vancouver BC Canada V6E 2E9
- IPO Date
- Feb 1, 2022
- CIK
- 0001969766
- Website
- asepmedical.com
- Similar Companies
- Business
- Asep Medical Holdings Inc (Ticker: SEPSF) is a medical technology company focused on developing innovative diagnostic and monitoring devices for healthcare applications. The company offers the SteriLid™ device, a hands-free eyelid speculum designed to optimize surgical performance during ophthalmic procedures by improving visibility and reducing contamination risks; the NovaEye® GN-100, a portable intraocular pressure measurement tool utilizing advanced tonometry technology for glaucoma assessment; and the CircuLite Intra-Atrial Blood Pump, a miniaturized circulatory support system aimed at treating heart failure patients through minimally invasive implantation. These products target ophthalmologists, cardiologists, and surgical centers, with operations centered in North America and expansion into European markets. Founded in 2015 and headquartered in Toronto, Canada, the company operates without notable subsidiaries or parent relationships. In the latest developments, Asep Medical Holdings Inc advanced its SteriLid™ commercialization efforts through a strategic distribution partnership with K1 Network Inc in 2024, enhancing market penetration in key surgical segments. The company also secured a significant financing round in early 2025, bolstering R&D for next-generation monitoring technologies amid growing demand for infection control solutions. No major acquisitions, name changes, or reorganizations have been reported in the past two years, though operational focus has shifted toward regulatory approvals for international launches.
CSE Bulletin: Reinstatement - ASEP Medical Holdings Inc. (ASEP)
CSE Bulletin: Consolidation - ASEP Medical Holdings Inc. (ASEP)
Asep Medical Featured in National Documentary
Asep Joint Venture Company, SepSMART, obtains Business License and is Formally Registered in China
Asep Medical Holdings Inc. to Hold Significant Investor Information Webinar this Friday, March 22, 2024, at 4 pm EST
Asep Medical Confirms the Use of AI - Enables Improved Treatments for Common Biofilm Infections and Rapid Sepsis Diagnostics
Asep Medical's Sepsis Diagnostic Technology Can Provide Improved Odds for Pediatric Appendicitis
ASEP INC. ANNOUNCES CLOSING OF DEBT SETTLEMENT
Asep Medical Holdings Inc. is Granted Patent Approval for its AI-based Sepsis Diagnostic Technology in the US
Asep Medical Holdings Inc. Signs Joint Venture Agreement with Leading Chinese Medical Diagnostics Company Sansure Biotech Inc.
Asep Inc. in Final Stage of Approval Process for NASDAQ Listing Registration Statement
Another Breakthrough-- Asep Inc.'s A.I.-Based Sepsis Technology Identifies COVID-19 Severity from a Blood Sample
Asep Inc. Completes Submission of Registration Statement for NASDAQ Listing